Shenzhen Innermed Medical Completes Tens of Millions RMB Financing Round; Gastrointestinal Ultrasound Endoscope Successfully Completes Clinical Trials

VCBeat (WeChat ID: vcbeat) has learned that Shenzhen Innermedical Medical Technology Co., Ltd. (“Innermedical”) recently announced the completion of a new round of financing amounting to tens of millions of yuan. The round was led by Yifeng Capital, with participation from Guiyang Venture Capital, Guozhong Venture Capital, Pengnian Venture Capital, Zhuangji Holdings, and other institutions. The proceeds will be primarily used to advance product commercialization and establish an initial market presence.

Innermedical, established in May 2015, is a national high-tech enterprise dedicated to providing original minimally invasive medical devices for the diagnosis and treatment of major diseases, such as cancer and cardiovascular and cerebrovascular disorders. The company currently focuses on minimally invasive interventional devices in cardiology and gastroenterology, with particular emphasis on the development of endoluminal interventional imaging products. Its three core products are ultrasound endoscopes, electronic endoscopes, and vascular imaging systems.

It is reported that Innermedical completed the clinical trials for its national innovative medical device product—the gastrointestinal endoscopic ultrasound system—in early July. Using a multicenter, paired-control clinical trial design, the product was compared with imported Olympus devices of the same type, demonstrating safety and efficacy that meet clinical requirements. The trial was led by Nanfang Hospital of Southern Medical University, with participation from Guangdong Provincial Hospital of Traditional Chinese Medicine and Dongguan People’s Hospital. Despite the absence of reference guidelines, the team successfully completed the study through persistent exploration, paving new ground for the development of domestically produced innovative medical devices. The product is currently undergoing registration submission and is expected to obtain Class III medical device registration shortly.

The company recently established its marketing team and achieved tens of millions in sales revenue in the first half of 2020. During the pandemic this year, the company actively participated in epidemic prevention efforts by donating anti-epidemic supplies to more than 60 hospitals across China. Its medically certified isolation eye shields and face shields have been exported to over 50 countries worldwide.

Yifeng Capital is a professional investment firm specializing in venture capital (VC) and private equity (PE) investments in the biopharmaceutical sector. Leveraging a global perspective, it deeply explores and integrates biopharmaceutical project resources. Its investment team is led by PhDs in biopharmaceutical-related disciplines from top-tier universities in China, the United States, Europe, Japan, and other regions, achieving a globally optimized talent structure and project resource layout. Recognized for its outstanding investment performance and excellent investment research capabilities, Yifeng Capital has received awards such as “China’s Most Dynamic Drug Innovation Investment Firm” and “China’s Best Emerging VC Manager,” and has been consecutively rated as one of the “Top Ten Venture Capital Firms in Shenzhen” for multiple years. It has also been featured and interviewed by Nature, a world-renowned scientific journal. Yifeng Capital has rigorously screened and invested in more than twenty high-quality domestic and overseas enterprises, including Mindray Medical, Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Pumen Technology, Apexigen, and Centrexion.

Guiyang Venture Capital Co., Ltd. (hereinafter referred to as “Guiyang VC”) is a venture capital enterprise established with the approval of the Guiyang Municipal People’s Government. Founded in 2010, the company’s current shareholders are Guiyang Industrial and Commercial Investment Group Co., Ltd. and Guiyang Wudang District State-owned Assets Operation Company, with a registered capital of RMB 350 million. Guiyang VC was honored as the “2017 China Best Government Industry Guidance Fund” and named one of Guizhou Province’s “Leading Enterprises of 2018.” The firm manages nine funds with assets under management exceeding RMB 4 billion, including government guidance funds and mixed-ownership venture capital funds. As a professional VC+FOF investment management institution, Guiyang VC is committed to supporting the rapid growth of small and medium-sized enterprises in their start-up and expansion phases that possess unique competitive advantages, aiming to serve as an incubator and accelerator for entrepreneurial ventures.

Shenzhen Pengnian Venture Capital Co., Ltd. was established in September 2018 and is registered in Luohu District, Shenzhen. Affiliated with the Hong Kong Pengnian Charitable Trust, the company boasts a robust industrial background and abundant resources in the healthcare and education sectors. Leveraging the strong capabilities and favorable social reputation of the Pengnian Group, Pengnian Venture Capital focuses its investments on healthcare, education, electronic information, artificial intelligence, and related fields. The company’s management team has over a decade of experience in venture capital, having invested in dozens of enterprises. Its investment decisions balance forward-looking vision with risk mitigation, and the team’s performance and credibility have been validated by both time and the market.

Zhuangji Holdings is a physical enterprise that has been developing in Shenzhen for many years. The company is a comprehensive industrial group with rich electronic component supply chains, marketing management consulting services, and e-commerce operation platforms. It has a nationwide new-type electronic professional market network facing the upstream and downstream of the industrial chain, creating an integrated high-end service platform that combines business flow, logistics, capital flow, and information flow.

Shenzhen Guozhong Venture Capital Management Co., Ltd. (hereinafter referred to as “Guozhong VC”) is a private equity investment institution specializing in the entrusted management of venture capital. It currently serves as the manager of the first physical fund of the National Small and Medium-sized Enterprise Development Fund, namely the SME Development Fund (Shenzhen Limited Partnership), with a scale of RMB 6 billion. Guided by in-depth research into industrial chains, Guozhong VC focuses on investment opportunities in strategic emerging industries, prioritizing outstanding enterprises in three key sectors: technological innovation, biopharmaceuticals and general health, and TMT (Technology, Media, and Telecom). Guozhong VC has won nearly 20 major awards in various industry evaluations. It has been listed among the Top 100 Best Venture Capital Institutions in China by Zero2IPO for three consecutive years, included in the List of China’s Best Venture Capital Institutions by CVSource for two consecutive years, and recognized as one of the Annual Best Venture Capital Institutions in the China Venture Capital Golden Eagle Awards by Securities Times for two consecutive years. Moreover, portfolio companies of Guozhong VC have frequently appeared on rankings published by authoritative industry institutions, accumulating more than 40 various awards.